M1FG
MDGL icon

Mach-1 Financial Group’s Madrigal Pharmaceuticals MDGL Stock Holding History

Mach-1 Financial Group’s Portfolio MDGL Stock Details MDGL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-1,064
Closed -$352K – 272
2025
Q1 		$352K Buy
+1,064
New +$350K 0.11% 154

Other funds holding MDGL

Janus Henderson Group
Janus Henderson Group London $209B AUM 37.72% 1-Year Est. Return
PC
Paulson & Co New York $2.58B AUM 68.51% 1-Year Est. Return
RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return

Mach-1 Financial Group's MDGL Position: Q2 2025 in Review

Mach-1 Financial Group sold out of Madrigal Pharmaceuticals (MDGL) in Q2 2025, closing a stake of 1,064 shares — an estimated $352K sold.

Mach-1 Financial Group first reported a position in MDGL in Q1 2025 and held it in 1 quarter. The position peaked at $352K in Q1 2025. 305 funds tracked by Wall St. Rank hold MDGL as of Q2 2025.

  • Mach-1 Financial Group reported no remaining Madrigal Pharmaceuticals position as of Q2 2025 after selling out during the quarter.
  • Mach-1 Financial Group sold 1,064 Madrigal Pharmaceuticals shares in Q2 2025, an estimated $352K.
  • Mach-1 Financial Group first reported a position in Madrigal Pharmaceuticals in Q1 2025 and held it in 1 quarter.
  • Mach-1 Financial Group's Madrigal Pharmaceuticals position peaked at $352K in Q1 2025.
  • 305 funds tracked by Wall St. Rank held Madrigal Pharmaceuticals as of Q2 2025.

Based on Mach-1 Financial Group's 13F filing for Q2 2025, filed 11 Aug 2025.